Promoter methylation of O-6-methylguanine-DNA methyltransferase (MGMT) is an important clinical predictor to overall survival time (OST) in gliomas and other cancers including colorectal cancer, lymphoma and lung cancer [7–10]. This evidence concerns the gene MGMT and lymphoma.